Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 6/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIF5B | P33176 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 13/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | ABL2 | P42684 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217847 | 0.97 | SRC (0.38) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217746 | 0.93 | NEK7 (0.37) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217976 | 0.92 | SRC (0.38) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217998 | 0.92 | SRC (0.42) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217624 | 0.88 | SRC (0.38) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217981 | 0.88 | SRC (0.38) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217863 | 0.87 | SRC (0.40) | SRCEGFR | |
| SCHEMBL27217684 | 0.85 | KDR (0.35) | RETKDRSRCEGFRABL1 | |
| SCHEMBL27217672 | 0.85 | SRC (0.38) | RIPK2RETKIF5BKDRKCNH2 | |
| SCHEMBL27217802 | 0.84 | EGFR (0.30) | KDRSRCEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | RIPK2 45/4885RET 2117/4885KIF5B 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.